TG Therapeutics Inc (TGTX)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	329,004	262,359	340,582	280,254	222,343	180,883	18,875	6,331	2,784	5,025	6,961	7,912	6,689	4,406	2,414	907	152	152	152	152
Receivables	US$ in thousands	129,185	115,727	83,608	64,982	51,093	39,320	17,484	8,623	0	—	88	903	1,389	1,384	931	771	—	—	—	—
Receivables turnover		2.55	2.27	4.07	4.31	4.35	4.60	1.08	0.73	—	—	79.10	8.76	4.82	3.18	2.59	1.18	—	—	—	—

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $329,004K ÷ $129,185K
= 2.55

The receivables turnover ratio for TG Therapeutics Inc has shown fluctuations over the periods analyzed. The ratio was not available (denoted by \u2014) for the first part of the data, indicating a lack of receivables turnover data. From March 2021 to June 2021, there was a significant improvement in the ratio from 1.18 to 2.59, indicating a faster turnover of receivables during this period. Subsequently, the ratio continued to increase steadily, reaching a peak of 79.10 in June 2022, suggesting a very rapid turnover of receivables.

However, from that point onwards, the ratio decreased notably in the following periods, indicating a slowdown in the collection of receivables. By December 2024, the receivables turnover ratio had stabilized at around 2.55, which is lower than the peak but still higher than some of the previous periods.

Overall, the trend in the receivables turnover ratio for TG Therapeutics Inc shows periods of improvement followed by some volatility and a subsequent stabilization at a moderate level. It would be important to further analyze the reasons behind these fluctuations to assess the effectiveness of the company's credit and collection policies.